bcゲーム リチャージ cats to veterinary clinics hourly 1 /release/202311132696 Fri, bcゲーム リチャージ 17:00:00 +0900 epitoMAP epitoMAP Inc. (hereinafter "epitoMAP") bcゲーム リチャージllergy Clinical Laboratories Inc. (hereinafter "... epitoMAP Inc.
epitoMAP Inc. (hereinafter "epitoMAP") bcゲーム リチャージllergy Clinical Laboratories Inc. (hereinafter "AACL") entered into a License Agreement for an antibody pharmaceutical for veterinary use, CRE-DR-B, with Nippon Zenyaku Kogyo Co., Ltd. (hereinafter "ZENOAQ") on November 10, 2023.

Logos:
epitoMAP :/img/bcゲーム リチャージ3-B5f8qrzL
ZENOAQ:/img/bcゲーム リチャージ5-QZ0646h5
AACL:/img/bcゲーム リチャージ4-Hw5TKcKs

Photos:
https://cdn.kyodonewsprwire.jp/prwfile/release/M107929/202311132696/bcゲーム リチャージrwbcゲーム リチャージI1fl_CUg5pN38.jpg

https://cdn.kyodonewsprwire.jp/prwfile/release/M107929/202311132696/bcゲーム リチャージrwbcゲーム リチャージI2fl_2gLRsvyi.jpg

Under the terms of the Agreement, ZENOAQ will have the right to conduct preclinical bcゲーム リチャージlinical development, manufacturing, bcゲーム リチャージommercialization of CRE-DR-B for use in allergic diseases such as canine atopic dermatitis in Japan. The main therapeutic effects of existing medicines on the market are to relieve the itching caused by allergies, whereas CRE-DR-B is able to prevent the production of IgE by eliminating its producing cells.

epitoMAP and AACL will utilize the upfront payment, milestone payment and royalties (the amount and other details are undisclosed) for the continuous development of CRE-DR-B overseas, humanized CRE-DR, and a pan-coronavirus therapeutic vaccine against future emerging variants of COVID-19 as well as feline infectious peritonitis (FIP) caused by a pathogenic coronavirus in cats, FIPV, aiming at their early commercialization. "This Agreement will accelerate our collaboration with human bcゲーム リチャージ pharmaceutical companies to develop these subsequent pipelines," said Kenichi Masuda, CEO of epitoMAP.

About CRE-DR-B
CRE-DR-B is a chimeric mouse x dog IgG-B antibody originated from CRE-DR, a unique mouse monoclonal antibody that binds to both human bcゲーム リチャージanine IgEs*. Since CRE-DR lacks binding to IgE on mast cells, the risk of anaphylactic shock as a major concern with anti-IgE antibody drugs can be avoided in the use of its antibody drugs. CRE-DR is able to remove the fundamental cause of allergy by eliminating and inactivating IgE-producing B cells. epitoMAP and AACL have so far succeeded in generating a caninized (CRE-DR-B) and a humanized antibody (CRE-DR-H). The commercialization of CRE-DR-B will demonstrate PoC, which can accelerate the development of CRE-DR-H.
*Publication:https://onlinelibrary.wiley.com/doi/10.1002/iid3.531

About Companies
epitoMAP is a "One Health" drug discovery venture established in July 2020, developing allergy therapeutics and vaccines that work for both humans bcゲーム リチャージs.
http://www.epitomap.co.jp/en

ZENOAQ is a leading company in the field of veterinary pharmaceuticals in Japan.
https://www.zenoaq.com/en/

AACL provides allergy and immunology testing services for dogs bcゲーム リチャージats to veterinary clinics.
http://www.aacl.co.jp/en_company/index.html

]]>